Abstract

The purpose of this Statement is to supplement previous conjugate meningococcal vaccine statements(1)-(4) which have outlined the use of monovalent meningococcal C and quadrivalent conjugate meningococcal vaccines. This statement will:

  • Review existing NACI recommendations on the use of conjugate meningococcal vaccines;
  • Update the epidemiology of meningococcal disease in Canada;
  •  Review and update information on quadrivalent conjugate meningococcal vaccines and vaccination schedules used in Canada following the approval of a new quadrivalent conjugate meningococcal vaccine Nimenrix™ (GlaxoSmithKline [GSK]) and of a new age indication for Menactra® (Sanofi Pasteur).
  • Recommendation
  • Americas
  • Canada
  • Meningococcal disease